The anti-migraine effect of BoNT-A is associated with relaxation of pathological muscle tension, anti-inflammatory effect, and affecting central afferent transport—includes inhibiting the release of substance P and CGRP (Ramachandran and Yaksh, 2014). The gene discussed is TAC1; the disease is migraine disorder.